BMC ophthalmology · 2025
12-month clinical outcomes of the Evolux™ extended monofocal intraocular lens following cataract surgery.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gabrić Krešimir, Jagić Mateja, Gabrić Ivana, Bohač Maja
Аннотация
PURPOSE: To evaluate the visual performance of a non-diffractive extended monofocal intraocular lens (Evolux™; SIFI, Catania, Italy) 12 months following cataract surgery.
METHODS: This retrospective, non-randomized, single-arm study included 116 eyes from 82 patients who underwent cataract surgery with Evolux™ IOL implantation. Patients underwent preoperative and postoperative assessments including uncorrected and best-corrected distance (UDVA, CDVA) and near visual acuity (UNVA, CNVA), as well as refractive accuracy and defocus curve evaluation. Postoperative measurements were recorded at 1, 3, 6, and 12 months.
RESULTS: At 12 months postoperatively, UDVA improved from 0.89 ± 0.54 logMAR to 0.10 ± 0.14 logMAR (p < 0.001), and CDVA improved from 0.41 ± 0.40 logMAR to 0.04 ± 0.08 logMAR (p < 0.001). 62% of eyes achieved a UDVA of 20/20 or better, while 96% reached at least 20/40. Refractive accuracy was high, with 76% of eyes achieving a postoperative spherical equivalent within ± 0.50 D and 95% within ± 1.00 D, indicating strong predictability. The defocus curve confirmed functional vision of 0.2 logMAR or better across a continuous defocus range of 2.00 D, supporting effective intermediate and near vision.
CONCLUSION: Evolux™ demonstrated good distance vision and enhanced intermediate vision without the visual disturbances commonly associated with multifocal or diffractive extended depth-of-focus IOLs. These findings suggest that Evolux™ is an effective solution for patients seeking greater spectacle independence and improved functional vision following cataract surgery.
METHODS: This retrospective, non-randomized, single-arm study included 116 eyes from 82 patients who underwent cataract surgery with Evolux™ IOL implantation. Patients underwent preoperative and postoperative assessments including uncorrected and best-corrected distance (UDVA, CDVA) and near visual acuity (UNVA, CNVA), as well as refractive accuracy and defocus curve evaluation. Postoperative measurements were recorded at 1, 3, 6, and 12 months.
RESULTS: At 12 months postoperatively, UDVA improved from 0.89 ± 0.54 logMAR to 0.10 ± 0.14 logMAR (p < 0.001), and CDVA improved from 0.41 ± 0.40 logMAR to 0.04 ± 0.08 logMAR (p < 0.001). 62% of eyes achieved a UDVA of 20/20 or better, while 96% reached at least 20/40. Refractive accuracy was high, with 76% of eyes achieving a postoperative spherical equivalent within ± 0.50 D and 95% within ± 1.00 D, indicating strong predictability. The defocus curve confirmed functional vision of 0.2 logMAR or better across a continuous defocus range of 2.00 D, supporting effective intermediate and near vision.
CONCLUSION: Evolux™ demonstrated good distance vision and enhanced intermediate vision without the visual disturbances commonly associated with multifocal or diffractive extended depth-of-focus IOLs. These findings suggest that Evolux™ is an effective solution for patients seeking greater spectacle independence and improved functional vision following cataract surgery.